Mid-Atlantic Bio Program to Highlight Innovative Partnering Models and Funding Sources

Sep 12, 2012

Mid-Atlantic Bio Program to Highlight Innovative Partnering Models and Funding Sources

Panelists to Address Range of Financing Opportunities, from SBIR and Angel Investors to Venture Capital and Partner Licensing Agreements

 Bethesda, Maryland (September 12, 2012) – Locating much-needed financing tops the list of nearly every biotech company, whether they need to move forward with additional research and development or need funding to bring a new product to market.  The 2012 Mid-Atlantic Bio Conference will give entrepreneurs and business leaders the opportunity to hear from, and network with, leaders at a variety of capital sources, including venture capital, angel and corporate investors; industry professionals and business leaders; peer scientists; grant and patient advocate program managers; and potential strategic partners.

By bringing in top-of-the-line speakers, attendees at the conference will get an insider’s look at translational research and commercialization; novel sources of capital; trends in development costs and funding opportunities through the Small Business Innovation Research (SBIR) program.

“We have heard from attendees that they want sessions that reflect the current marketplace for partnering, collaborating and connecting in what many view as an elusive financing environment. This year’s panels contain the best minds in biotech and finance and will give insight into how to create valuable business partnerships, as well as explore additional traditional as well as non-traditional funding sources to bring innovative products to market,” said Julia Spicer, Executive Director of Mid-Atlantic Venture Association.

In addition to attending panel sessions, attendees will have the opportunity to use BioMatch, a mobile app program (iPhone or Android) that helps facilitate interaction and networking.  This new business networking tool offers a robust online and mobile platform for sharing company and product information and set up and track one-on-one meetings at the conference.

This year’s conference takes place September 27-28 in Bethesda, MD.

Innovative Partnering Models for Moving Bioscience Discoveries to the Marketplace  
Join members of the university, corporate, investor and NIH communities to look at several innovative models in translational research and commercialization, to assess what is working and what opportunities are available.

Moderator: Mark Crowell, Executive Director, UVa Innovation and Associate Vice President for Research, University of Virginia

Panelists:

Anthony Coyle, PhD, VP/CSO, Centers for Therapeutic Innovation, Pfizer Inc.
Todd Chappell, BioHealth Innovation, Entrepreneur in Residence, NIH
Christopher P. Austin, M.D., Director, NCATS Division of Pre-Clinical Innovation, National Center to Accelerate Translational Science

Novel Capital Sources for Bioscience Companies
With venture funding dollars decreasing overall, companies must continue to look for novel ways to fund their research. This discussion brings a mix of funding programs created to capture larger audiences.  To ensure you have the right information to fund your programs, our panel members will discuss these options and more.

Moderator: Peter Ginsberg, Vice President for Business and Technology Development, The North Carolina Biotechnology Center

Panelists
Margaret Anderson, Executive Director, FasterCures
John Hollway, President, Pragmatos Consulting
Freeman White, CEO Launcht and Participating Member, Crowd funding Intermediary Regulatory Advocates
David Sandak, Vice President for Research and Business Development, Accelerate Brain Cancer Cure (ABC2)

New Developments in Traditional and Corporate Venture Capital
Join the panelists as they discuss shifts at the FDA, implications of the PDUFA V legislation, and trends in overall development costs (“virtual models” to reduce burn, companion diagnostics, and development in / partnerships for ex-U.S. markets).  Panelists will also examine exits appetite for mid- to late-stage healthcare companies among public investors, big pharma/big device company interest in mid-stage products, and implications of recent liquidity trends for the venture capital industry.

 Moderator: Nina Kjellson, General Partner, InterWest Partners

Panelists

Art Pappas, Managing Partner, Pappas Ventures
Brian Gallagher, Ph.D., Partner, SR One
Robert Weisskoff, Ph.D., Partner, Fidelity Biosciences
David Berry, M.D., Ph.D., Partner, Flagship Ventures

SBIR/STTR: Strategies, Program Changes and Current Opportunities
In the first of this special two-hour session, experts will describe the changes in rules proposed to implement recent reauthorization, and will also discuss the strategic role of SBIR/STTR and non-dilutive funding in the financial strategy of a startup.  In the second hour, program representatives from leading NIH Institutes will describe current open funding opportunities, and will be available for one-on-one breakout discussions with attendees.

 Panelists
Matt Portnoy, NIH SBIR/STTR Program Coordinator, Director, Division of Special Programs, OEP, OER, NIH, DHHS
Christy Shaffer, PhD, Venture Partner and Managing Director, Hatteras Venture Partners
Kurt Marek, Program Director SBIR coordinator, National Heart Lung Blood Institute (NHLBI)
Stephanie Fertig, Research project manager SBIR Program, National Institute of Neurological Disorders and Stroke (NINDS)
Jennifer Shieh, AAAS Science & Technology Policy Fellow, SBIR Development Center, National Cancer Institute (NCI)

About Mid-Atlantic Bio
Mid-Atlantic Bio – taking place September 27-28 in Bethesda, Md. – is one of the country’s premier biotech conferences for senior-level executives, policymakers, academia, financiers, media and service providers. Its proximity to the US government, federal labs, commercial research and development, academic centers of excellence and a growing investment community, make it a uniquely valuable venue for those in the life sciences community. First launched as an industry gathering at the Academies of Science, the conference is a joint initiative of the founding host organizations: the Mid-Atlantic Venture Association, the Virginia Biotechnology Association, and the Tech Council of Maryland. The Conference is also pleased to welcome the North Carolina Biotechnology Center as a strategic partner for 2012. For more information, please visit midatlanticbio.org.
For the latest news and updates: follow us on Twitter @MidAtlanticBio or join our LinkedIn and Facebook groups.

CONTACT:
Audrey Chang
(202) 295-8779
media@midatlanticbio.org